Antibiotic resistance among major pathogens compared to hospital treatment guidelines and antibiotic use in Nordic hospitals 2010-2018.

• Published in: Infectious Diseases
• Main Authors: Möller, Vidar, Östholm-Balkhed, Åse, Berild, Dag, Fredriksson, Mats, Gottfredsson, Magnus, Holmbom, Martin, Järvinen, Asko, Kristjansson, Mar, Rydell, Ulf, Sönksen, Ute Wolff, Kolmos, Hans Joern, Hanberger, Håkan
• Other Authors: 1Department of Biomedical and Clinical Sciences, Faculty of Medicine, Linköping University, Linköping, Sweden. 2Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway. 3Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 4Landspitali University Hospital, Reykjavik, Iceland. 5University of Iceland, Reykjavik, Iceland. 6Division of Infectious Diseases, Helsinki University Hospital and Helsinki University, Helsinki, Finland. 7Statens Serum Institut, Copenhagen, Denmark. 8Odense University Hospital, Odense, Denmark.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Taylor & Francis 2021
• Subjects: Antibiotic resistance; Nordic countries; antibiotic stewardship; practice guidelines as topic; Sýklalyfjaónæmi; Norðurlandabúar; Drug Resistance; Microbial; Scandinavian and Nordic Countries; Norway; Iceland
• Online Access: http://hdl.handle.net/2336/621850; https://doi.org/10.1080/23744235.2021.1910338

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download Antibiotic resistance levels among Escherichia coli and Klebsiella pneumoniae were similar in all Nordic countries in 2018 and low compared to the European mean. Guidelines for acute pyelonephritis varied; 2nd generation cephalosporin (Finland), 3rd generation cephalosporins (Sweden, Norway), ampicillin with an aminoglycoside or aminoglycoside monotherapy (Denmark, Iceland and Norway). Corresponding guidelines for sepsis of unknown origin were 2nd (Finland) or 3rd (Sweden, Norway, Iceland) generation cephalosporins, carbapenems, (Sweden) combinations of penicillin with an aminoglycoside (Norway, Denmark), or piperacillin-tazobactam (all Nordic countries). Methicillin-resistant Staphylococcus aureus rates were 0-2% and empirical treatment with anti-MRSA antibiotics was not recommended in any country. Rates of penicillin non-susceptibility among Streptococcus pneumoniae were low (<10%) except in Finland and Iceland (<15%), but benzylpenicillin was recommended for community-acquired pneumonia in all countries. Region Ostergotland Vinnova